#MEDPRIN 3d prints world first biological meningioma Redura for use in brain surgery While 3d bioprinting innovations sound lifesaving and revolutionary, most are still years away from impacting ordinary
Called MEDPRIN, they have developed the world first 3d printed biological meningioma called Redura a replica of tissue covering the brain
When patching everything up, they'paste'an artificial Meningioma layer on the area in question and sew everything together.
and have a tendency to disrupt a patient life-as most artificial meningioma layers contain metal parts
Over a course of up to three months, a completely new Meningioma beings to grow, while the artificial structure naturally degrades.
#Plasmons Influence Carbon-Based Nanoparticles for Sensitizing Cancerous Tumors In a study published in EPJ D,
stretchy electronic sensors are also capable of detecting harmful levels of UV radiation known to trigger melanoma.
The sensor will enable doctors to identify tumor markers, whose presence in the body signals the emergence and growth of cancerous tumors.
The sensitivity of the new device is characterized best by one key feature: according to its developers, the sensor can track changes of just a few kilodaltons in the mass of a cantilever in real time.
then affix the nanoparticles to antibodies targeting malignant tumors and put them in a liquid that cancer patients could take via a single injection.
Theoretically, the nanoparticles would attach to the tumor and emit low energy electrons, destroying the tumor DNA.
The gold-based nanoparticles would be flushed out of the body, Sykes says, unlike free iodine-125,
into tiny titanium capsules and implanting them in tumors. Instead of emitting large amounts of low energy electrons as the gold-bound iodine does,
which was the first genetic-based approach that is able to detect live circulating tumor cells out of the complex matrix that is human blood.
#Study paves way for genetics-first approach to brain cancer treatment Two US studies have identified specific genetic mutations in gliomas
'This molecular data helps us better classify glioma patients, so we can begin to understand who needs to be treated more aggressively
Gliomas are tumours which develop from the glial cells of the brain and spine, and make up 80 percent of malignant brain tumours.
Patients who develop gliomas are treated usually with a combination of radiotherapy, surgery and chemotherapy; however it is currently difficult to work out how useful these treatments will be.
three mutations were identified in patients with gliomas. Tumours taken from glioma patients were scored as positive or negative for these mutations,
which led to the creation of five categories of mutation combinations. The genetic profiles of the tumours were associated then with patient age, prognosis and the response of the tumour type to different treatments.
This profiling would allow doctors to choose the most appropriate treatment for an individual glioma patient based on their genetic classification.
as survival statistics would be specific to the glioma type, as opposed to the general class of glioma.
Currently histology is used to classify gliomas by their visual characteristics; however this method is not sufficiently effective to predict how the glioma will respond to therapy.
Doctors are also often unable to predict how aggressive a tumour will behave over a long period of time.'
'These markers will potentially allow us to predict the course of gliomas more accurately, treat them more effectively
and identify more clearly what causes them in the first place, 'said Professor Margaret Wrensch from the University of California,
'Both studies can justifiably claim that molecular classification captures the biologic features of glioma variants better than does histopathological evaluation,
Heather and Melanie Muss Endowed Chair and a principal investigator in the UCSF Brain tumor Research center and the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research. t may be unwelcome
such as the B-allele frequency plot, that have been optimized for the identification of biologically relevant genomic variants in tumor samples s
tumor growth, metastasis, recurrence and drug resistance. In epithelial cancers cancers of the breast, ovaries, prostate, skin and bladder,
or sirna, into tumor cells. In mouse models, delivering sirna into cancer cells inhibited the expression of Twist,
and dramatically reduced the size of tumors. The study, which was published online in the journal Nanomedicine:
and encourages us to explore further what is happening to the tumor. In previous studies
sirna has been shown to effectively shut down gene expression in tumor cells grown in the laboratory. But the technique had not been effective in living organisms
because enzymes in the blood called nucleases degrade sirna before it can reach tumor cells.
the nanoparticles could accumulate in the tumor cells and the sirna could go to work inhibiting the cellsexpression of Twist.
The study found that giving mice sirna-loaded nanoparticles once a week for six weeks inhibited tumor growth,
which promotes tumor invasion and metastasis in many cancers, said Glackin, an associate professor at the City of Hope who has been studying the function of Twist for 20 years.
melanoma and ovarian cancer. By shutting down the epithelialesenchymal transition process, Zink and Tamanoi may develop new therapy options for these cancers.
genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
where myeloma tumors typically are showed found, and a long-term ability to fight the tumors. Relapse was associated generally with a loss of the engineered T-cells. his study suggests that treatment with engineered T-cells is not only safe
but of potential clinical benefit to patients with certain types of aggressive multiple myeloma, says first author Aaron P. Rapoport, M d,
In the clinical study, patientst-cells were engineered to express an affinity-enhanced T-cell receptor (TCR) specific for a type of tumor antigen,
which correlates to tumor proliferation and poorer outcomes. According to Adaptimmune, the trial is published the first study of lentiviral vector mediated TCR gene expression in humans.
as scientists have shown that using drugs to block PD-1 coaxes T cells to attack tumors.
which covers differentiated thyroid cancer as well as medullary thyroid carcinoma and anaplastic thyroid carcinoma. Discovered at Eisai's Tsukuba Research Laboratories
which are involved especially in tumor angiogenesis and proliferation of thyroid cancer. Furthermore, Lenvima has been confirmed through X-ray co-crystal structural analysis to demonstrate a new binding mode (Type V) to VEGFR2,
and has demonstrated clinically target tumor regression (tumour shrinkage) in both solid tumor indications of pancreatic and liver cancer.
"The company also announced the appointment of Professor Pierce Chow as chairman to lead primary liver cancer-hepatocellular carcinoma (HCC)- Scientific Advisory board d
#Detecting potent tumors using a smartphone! Ms Maryam Sadeghi shows off an early version of Molescope (Picture courtesy:
whether the tumor is benign or malignant in a study of 20 patients,"said Mr Yuki Hasegawa of My Tech.
and malignant tumors on hormone-producing organs such as the parathyroid gland, the pancreas and the pituitary gland. Animal studies previously linked this gene mutation with breast cancer;
including circulating tumor cells from blood, paving the way for better cancer treatments. The project will get access both to the BIO-X process support
"My Phd supervisor, she found her melanoma when she was designing the device, just testing the image quality,"said Sadeghi."
which was the first genetic-based approach that is able to detect live circulating tumor cells out of the complex matrix that is human blood.
and shrink tumor growth. Jerry W. Shay, Ph d.,professor and vice chairman of cell biology at UT Southwestern,
and colleague, Woodring E. Wright, M d.,Ph d.,professor of cell biology and internal medicine, found that 6-thio-2'-deoxyguanosine could stop the growth of cancer cells in culture and decrease the growth of tumors in mice.
6-thio-dg caused a decrease in the tumor growth rate superior to that observed with 6-thioguanine treatment.
In addition, 6-thio-dg increased telomere dysfunction in tumor cells in vivo. These results indicate that 6-thio-dg may provide a new telomere-addressed telomerase-dependent anticancer approach."
as well as tumor burden shrinkage in mice,"noted Dr. Shay, who is also associate director of the Harold C. Simmons Comprehensive Cancer Center.
but these drugs have to be administered for long periods of time to successfully trigger cell death and shrink tumors,
because cells in any one tumor have chromosomes with different telomere lengths and any one cell's telomeres must be shortened critically to induce death. 6-thiodg is used preferentially as a substrate by telomerase
in addition to uncovering a gene that may aid tumors in promoting resistance to existing drug therapies.
According to the authors, this is the first study of its kind to use whole-exome sequencing to probe testicular germ cell tumors,
examined tumor samples from 42 patients with testicular cancer. They report previously unidentified chromosome duplications and confirmed data from earlier findings that associated these tumors with the KIT gene,
which has been linked to an array of other cancerous tissues.""Our study is the largest comprehensive sequencing study of testicular tumors published to date,
describing their mutational profile in greater detail than has been possible using previous technologies, says Clare Turnbull, Ph d.,senior author and team leader in predisposition and translational genetics at ICR.
Their preliminary finding of a link between XRCC2 and platinum drug resistance was validated once they sequenced a sample from an additional platinum-resistant tumor. e have identified new potential driver mutations for this type of cancer
This study provides essential general knowledge concerning testicular germ line cell tumor development but more importantly, valuable insight into the genetic underpinnings as to why certain patients develop resistance to chemotherapy h
#New Microchip Design Captures Circulating Tumor Cells Circulating tumor cells (CTCS) represent the metastatic seed that can break away from the primary tumor site,
"The findings from this study were published recently in Nature Methods through an article entitled"A microfluidic device for label-free, physical capture of circulating tumor cell clusters."
and melanoma cancers. The researchers observed CTC clusters ranging from 2-19 cells among 300%of the patients."
31%of prostate and 30%of melanoma patientsuggestive of a greater role for CTC clusters in metastatic cancers than previously thought.
Interestingly, the data from this small study also showed a rare presence of non-tumor derived immune cells within clusters,
the ability to monitor tumor-immune cell interactions via the blood could be of great value."
However, data in recent years is beginning to bring into focus that many prostate tumors display substantial amounts of genetic heterogeneity, leading to differential mortality rates.
as well as identifying a new gene subgroup acting as a molecular driver for tumor progression. ur research shows how prostate cancers can vary from one man to anotherespite the same pathology under the microscopes well as how it can vary within one man who may have multiple
tumor types in his prostate, "explained Robert Bristow, M d.,Ph d.,clinician-scientist at Princess Margaret Cancer Centre,
The investigators carefully analyzed the genetic backgrounds of each tumor sample, assigning individual aggression scores to the discreet cancer foci regions they identified.
Dr. Bristow and his colleagues identified two members of the MYC oncogene family that played essential roles in tumor development.
which has already been implicated in lung cancer development, playing a critical role in tumor progression.""This discovery of a new prostate cancer-causing gene gives researchers a new avenue to explore the biology of the disease
"By showing that mutations in prostate cancer vary spatially in different regions of a tumor,
"This allowed us to find a drug that targeted ULK1 not just in a test tube but also in tumor cells.
Our work provides the basis for a novel drug that will treat resistant cancer by cutting off a main tumor cell survival process. i
and in human tumor cells in the lab, showed that a specific drug can stop cancer cells without causing damage to healthy cells or leading to other severe side effects.
In fact, this is how doctors use positron emission tomography to scan images to spot tumors. PET scans highlight the glucose that cancer cells have accumulated.
In a paper (road Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis published in Cancer cell
Dr. Burris reports that the Warburg effect is the metabolic foundation of oncogenic growth, tumor progression,
and metastasis as well as tumor resistance to treatment.""Cancer cells look for metabolic pathways to find the parts to grow and divide.
and in human tumor cells grown in animal models. Because the Warburg pathway is a feature of almost every kind of cancer,
"It works in a wide range of cancers both in culture and in human tumors developing in animal models,"explained Dr. Burris."
"In human tumors grown in animal models, it reportedly worked well on lung, prostate, and colorectal cancers and, to a lesser degree, in ovarian and pancreatic cancers."
which was carried out on human tumor samples and mouse models, is published in the Proceedings of the National Academy of Sciences.
which has been linked to a range of tumors in different body organs. The mitotic spindle is responsible for sharing the chromosomes
Cutting off a cancer cell ood supplyis a veritable lynchpin for the efficient removal of tumors and now researchers at the University of Texas MD Anderson Cancer Center believe they may have found a protein that serves that very function.
and also serve to protect cells from the transformation into tumors.""We know that all cancers grow by learning how to reprogram their metabolism,
and reverses tumor-promoting metabolic programs.""The findings from this study were published recently in Nature Communications through an article entitled ell cycle regulator 14-3-3s opposes
such as p53 and suppress tumor growth, but in this instance the investigators were able to observe the protein acting on metabolic pathways
Dr. Lee and his team showed that 14-3-3s opposed tumor-promoting metabolic programs by increasing the degradation of the transcription factor c-Myc.
as well as a range of other major metabolic processes of tumors.""14-3-3s expression levels can help predict overall and recurrence-free survival rates, tumor glucose uptake,
and metabolic gene expression in breast cancer patients,"explained Dr. Lee.""These results highlight that 14-3-3s is an important regulator of tumor metabolism,
and loss of 14-3-3s expression is critical for cancer metabolic reprogramming.""The MD Anderson team is excited about the findings from this new study
"We anticipate that pharmacologically elevating 14-3-3s's function in tumors could be a promising direction for targeted anticancer metabolism therapy development in the future,"concluded Dr. Lee r
but activate the body's own immune system to stave off harmful tumors. The clinical trial was conducted across 64 research centers around the world
What's more, T-VEC is designed also to produce a molecule known as GM-CSF that moves the body's immune system to destroy tumors
Patients with stage III and early stage IV melanoma a condition that was shown to carry an average survival of 21.5 months
The scientists say that T-VEC is the first of such viral therapies to be proven beneficial in treating melanoma in a phase III clinical trial.
or face so that tumors can be removed from the pituitary gland and skull base. It can also be done through the nasal cavity with an endoscope (a thin tube with a camera attached),
which accumulate in tumor cells and scatter light making the tumors easy to see with a special camera.
The particles are each about 140 nanometers (0. 000005 inches) across and consist of eight-point gold stars that are surrounded by a layer of dye
and tumor cells that researchers had suspected existed but hadn't seen. It was thought precancerous cells also develop the larger pores like cancer cells.
but don't know where edges of the tumor are. So doctors either have to take out all of the tissue that might possibly contain cancer
. and China of patients suspected of having malignant squamous cell tumors, the device was used alongside a regular endoscope.
and adrenocorticotropic hormone (ACTH) from normal human pituitary gland and pituitary adenoma tissue sections, using a fully automated droplet-based liquid-microjunction surface-sampling-HPLCSI-MSS system for spatially resolved sampling, HPLC separation,
and non-secreting pituitary adenomas correlated with histopathological evaluation a
#Brainport V100 Turns Your Tongue Into an Eye If you can see with your eyes,
#Optical Probe to Help Remove Only Cancerous Tissues in Brain Surgeries Neurosurgeons removing a tumor have to be obsessive about resecting just enough
Tumors usually look the same as the healthy tissue just around them, which means the repeated biopsies
the fact that tumors tend to be denser was the basis for many designed devices,
This method is used to study the spatiotemporal mechanical response of MDA-MB-231 breast carcinoma cells to the inhibition of Syk protein tyrosine kinase giving insight into the signaling pathways by which Syk negatively regulates motility of highly invasive cancer cells.
not just identification of risk of tumors, would be said a major advancement Dr. Hemant K. Roy professor of medicine and Chief of gastroenterology at Boston Medical center and an author of the study."
2015innovative light therapy reaches deep tumors March 9th, 2015a new tool for detecting and destroying norovirus March 9th,
March 10th, 2015photonics/Optics/Lasers Innovative light therapy reaches deep tumors March 9th, 2015quantum sensor's advantages survive entanglement breakdown:
#Microchip captures clusters of circulating tumor cells--NIH study Circulating tumor cells (CTCS) are cells that break away from a tumor and move through a cancer patient's bloodstream.
and melanoma cancers. The researchers found CTC clusters--ranging from two to 19 cells--in 30-40 percent of the patients."
and occasionally clusters using antibodies that stick to special proteins found on the surface of some tumor cells.
including those that lose surface proteins during metastasis and those that never express them, such as melanoma.
In this study, the chip captured CTC clusters in 11 of 27 (40.7 percent) breast cancer patients, 6 of 20 (30 percent) melanoma patients
the researchers measured a marker of tumor cell proliferation--an indicator of increased invasiveness and poor outcomes--in one breast cancer patient with high numbers of both single CTCS and clusters.
The researchers also noted the rare presence of non-tumor cells within clusters in less than 5 percent of patients."
the ability to monitor tumor-immune cell interactions via the blood could be of great value."
New device offers clues Why do some cancer cells break away from a tumor and travel to distant parts of the body?
"A primary tumor is not what kills patients. Metastases are what kill patients. Understanding which cells are likely to metastasize can help us direct more targeted therapies to patients,
Which cells in this patient's tumor are really causing havoc? Is there a large population of aggressive cells?
"Understanding specific differences that lead some cancer cells to leave the primary tumor and seed metastases is of great benefit to develop
Simple design mimics pumping mechanism of life-sustaining proteins found in living cells May 19th, 2015studying dynamics of ion channels May 18th, 2015organic nanoparticles, more lethal to tumors:
Carbon-based nanoparticles could be used to sensitize cancerous tumors to proton radiotherapy and induce more focused destruction of cancer cells, a new study shows May 18th,
more lethal to tumors: Carbon-based nanoparticles could be used to sensitize cancerous tumors to proton radiotherapy
and induce more focused destruction of cancer cells, a new study shows May 18th, 2015wearables may get boost from boron-infused graphene:
#Nanotechnology identifies brain tumor types through MRI'virtual biopsy'in animal studies: If results are confirmed in humans,
tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections;
new NIH grant will fund future study Abstract: Biomedical researchers at Cedars-Sinai have invented a tiny drug-delivery system that can identify cancer cell types in the brain through"virtual biopsies
and fight tumor cells in the brain without resorting to surgery.""Our nanodrug can be engineered to carry a variety of drugs,
proteins and genetic materials to attack tumors on several fronts from within the brain,"said Julia Ljubimova, MD, Phd,
such as seeking out cancer cells and binding to them, permeating the walls of blood vessels and tumor cells,
or dismantling molecular mechanisms that promote tumor growth, "said Eggehard Holler, Phd, professor of neurosurgery and director of nanodrug synthesis at Cedars-Sinai.
diagnosing brain tumors by identifying cells that have spread to the brain from other organs, and then fighting the cancer with precise, individualized tumor treatment.
Researchers can determine tumor type by attaching a tracer visible on an MRI. If the tracer accumulates in the tumor,
it will be visible on MRI. With the cancer's molecular makeup identified through this virtual biopsy,
researches can load the"delivery system"with cancer-targeting components that specifically attack the molecular structure.
Brain tumor Center and the Ruth and Lawrence Harvey Chair in Neuroscience.""The nanodrug is engineered to cross this barrier with its payload intact,
May 27th, 2015fine-tuned molecular orientation is key to more efficient solar cells May 26th, 2015cancer Iranian Scientists Use Magnetic field to Transfer Anticancer Drug to Tumor Tissue May 24th,
Scientists Use Magnetic field to Transfer Anticancer Drug to Tumor Tissue May 24th, 2015discoveries Who needs water to assemble DNA?
"The team tested the therapeutic potential of the nanoparticles by loading them with an anti-melanoma drug
In further experiments, the researchers found they could alter the infusion of the particles into melanoma cells by adjusting the polymer coatings.
"This is a versatile platform to carry a multitude of drugs-for melanoma, for other kinds of cancers and for other diseases,
but it is our hope that this could one day be used to deliver drugs directly to spinal cord injuries, ulcerations, deep bone injuries or tumors,
#Nanospheres shield chemo drugs, safely release high doses in response to tumor secretions Scientists have designed nanoparticles that release drugs in the presence of a class of proteins that enable cancers to metastasize.
and build that into a nanoscale carrier that can seek out a tumor and deliver a payload of drug,
The shell fragments form a ragged mesh that holds the drug molecules near the tumor.
builds on his group's earlier sucess using a similar strategy to mark tumors for both diagnosis and precise surgical removal.
That means the drug was inactivated as it flowed through the circulatory system until it reached the tumor.
in a test in mice with grafted in fibrosarcoma tumors. In additional preliminary tests, Callmann and colleagues were able to halt the growth of the tumors for a least two weeks,
using a single lower dose of the drug. In mice treated with the nanoparticles coated with peptides that are impervious to MMPS or given saline,
the tumors grew to lethal sizes within that time. Gianneschi says they will broaden their approach to create delivery systems for other diagnostic and therapeutic molecules."
This can allow scientists to see fine features of objects such as tumors, or minute flaws within airplane wings in industrial testing, that may otherwise be unobservable due to an instrument's diffractive limit.
This process activates the T cells to ward off a virus, bacteria or tumor, as well as to make more T cells.
humans with magnetic aapcs bearing antigens from tumors. They then ran the plasma through a magnetic column.
The tumor-fighting T cells bound to aapcs and stuck to the sides of the column,
which relies on other white blood cells called tumor-infiltrating lymphocytes. Those cells are trained already"to fight cancer,
and researchers have shown some success isolating some of the cells from tumors, inducing them to divide,
because not all have tumor-infiltrating lymphocytes. By contrast, all people have naive T cells, so patients with cancer could potentially benefit from the new approach
whether or not they have tumor-infiltrating lymphocytes.""The aapcs and magnetic column together provide the foundation for simplifying
and streamlining the process of generating tumor-specific T cells for use in immunotherapy, "says Juan carlos Varela, M d.,Ph d,
which they say could help combat the problem of tumors mutating to evade the body's defenses."
safely release high doses in response to tumor secretions July 14th, 2015chemotherapeutic coatings enhance tumor-frying nanoparticles:
Duke university researchers add a drug delivery mechanism to a nanoparticle therapy already proven to target,
heat and destroy tumors July 13th, 2015super graphene can help treat cancer July 10th, 2015govt. -Legislation/Regulation/Funding/Policy Researchers Build a Transistor from a Molecule and A few Atoms July 14th, 2015world first:
safely release high doses in response to tumor secretions July 14th, 2015better memory with faster lasers July 14th,
safely release high doses in response to tumor secretions July 14th, 2015chemotherapeutic coatings enhance tumor-frying nanoparticles:
Duke university researchers add a drug delivery mechanism to a nanoparticle therapy already proven to target,
heat and destroy tumors July 13th, 2015magnetic hyperthermia, an auxiliary tool in cancer treatments July 8th, 2015discoveries For faster,
safely release high doses in response to tumor secretions July 14th, 2015globalfoundries Completes Acquisition of IBM Microelectronics Business:
New device offers clues (Nanowerk News) Why do some cancer cells break away from a tumor and travel to distant parts of the body?
"A primary tumor is not what kills patients. Metastases are what kill patients. Understanding which cells are likely to metastasize can help us direct more targeted therapies to patients,
Which cells in this patient's tumor are really causing havoc? Is there a large population of aggressive cells?
"Understanding specific differences that lead some cancer cells to leave the primary tumor and seed metastases is of great benefit to develop
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011